These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22639052)

  • 21. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.
    Kim TD; Rea D; Schwarz M; Grille P; Nicolini FE; Rosti G; Levato L; Giles FJ; Dombret H; Mirault T; Labussière H; Lindhorst R; Haverkamp W; Buschmann I; Dörken B; le Coutre PD
    Leukemia; 2013 Jun; 27(6):1316-21. PubMed ID: 23459449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
    Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
    Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience with dasatinib and nilotinib use in pregnancy.
    Barkoulas T; Hall PD
    J Oncol Pharm Pract; 2018 Mar; 24(2):121-128. PubMed ID: 29284357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia.
    Rea D; Mirault T; Raffoux E; Boissel N; Andreoli AL; Rousselot P; Dombret H; Messas E
    Leukemia; 2015 May; 29(5):1206-9. PubMed ID: 25482133
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
    Tokuhira M; Kimura Y; Sugimoto K; Nakazato T; Ishikawa M; Fujioka I; Takaku T; Iriyama N; Sato E; Fujita H; Hatta Y; Komatsu N; Asou N; Kizaki M; Kawaguchi T
    Med Oncol; 2018 Feb; 35(3):38. PubMed ID: 29442179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML.
    Rosti G; Castagnetti F; Gugliotta G; Palandri F; Baccarani M
    Cancer Treat Rev; 2012 May; 38(3):241-8. PubMed ID: 21840128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
    Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
    Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy: a single-center retrospective study].
    Edahiro Y; Takaku T; Konishi H; Tsukune Y; Fujioka I; Takasu K; Gotoh A; Daida H; Komatsu N
    Rinsho Ketsueki; 2017; 58(11):2213-2218. PubMed ID: 29212971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report.
    Hanley B; Nesr G; Yebra-Fernandez E; Brown L; Rabitsch A; Killeen N; Claudiani S; Milojkovic D; Kanfer E; Apperley J; Naresh KN
    J Clin Pathol; 2019 Jul; 72(7):511-512. PubMed ID: 31004076
    [No Abstract]   [Full Text] [Related]  

  • 30. The link between interleukin-1β and acute myocardial infarction in chronic myeloid leukemia patients treated with nilotinib: cross-sectional study.
    Mori H; Sukegawa M; Fukatsu M; Sano T; Takahashi H; Harada K; Kimura S; Ohkawara H; Nakamura K; Mita M; Saito T; Hamazaki Y; Ohta M; Ikezoe T
    Ann Hematol; 2020 Feb; 99(2):359-361. PubMed ID: 31872359
    [No Abstract]   [Full Text] [Related]  

  • 31. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
    Wei G; Rafiyath S; Liu D
    J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nilotinib (Tasigna) for CML.
    Med Lett Drugs Ther; 2008 Apr; 50(1283):26-7. PubMed ID: 18391899
    [No Abstract]   [Full Text] [Related]  

  • 33. Double-edged sword of the new cancer therapeutics.
    Force T
    Circulation; 2012 May; 125(17):2057-8. PubMed ID: 22451582
    [No Abstract]   [Full Text] [Related]  

  • 34. Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib.
    Spataro V
    J Clin Oncol; 2011 Jan; 29(3):e50-2. PubMed ID: 20956624
    [No Abstract]   [Full Text] [Related]  

  • 35. A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.
    Suemori K; Fujiwara H; Watanabe S; Azuma T; Yasukawa M
    Int J Hematol; 2010 Dec; 92(5):777-8. PubMed ID: 21110146
    [No Abstract]   [Full Text] [Related]  

  • 36. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
    Cashen A; DiPersio JF; Khoury H
    J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
    [No Abstract]   [Full Text] [Related]  

  • 37. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
    Li N; Yang X; Fan L; Totev T; Guerin A; Chen L; Bhattacharyya S; Joseph G
    J Med Econ; 2017 Apr; 20(4):328-336. PubMed ID: 27841717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
    Woo SM; Huh CH; Park KC; Youn SW
    J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
    [No Abstract]   [Full Text] [Related]  

  • 39. Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells.
    Kaune KM; Baumgart M; Gesk S; Mitteldorf C; Baesecke J; Glass B; Haase D; Siebert R; Ghadimi BM; Neumann C; Emmert S
    Arch Dermatol; 2008 Mar; 144(3):361-4. PubMed ID: 18347292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
    Giles FJ; Yin OQ; Sallas WM; le Coutre PD; Woodman RC; Ottmann OG; Baccarani M; Kantarjian HM
    Eur J Clin Pharmacol; 2013 Apr; 69(4):813-23. PubMed ID: 23052406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.